MMED Q1 organic revenue rises 16%; fiscal 2027 guidance raised
MMED reported Q1 delivered 16% organic revenue growth, driven by strong U.S. and international performance plus new product launches and expanding recurring revenue.
Q1 delivered 16% organic revenue growth, driven by strong U.S. and international performance, new product launches, and expanding recurring revenue streams.
Fiscal 2027 guidance was raised, with margin expansion expected as separation costs decline and new products ramp globally.Based on MiniMed Gr…